Strickland, Eunice S. Wang, Kristina M. Gregory and Maoko Naganuma
暂无分享,去创建一个
M. Millenson | F. Appelbaum | D. Arber | M. Tallman | R. Stone | B. Smith | J. Lancet | C. Abboud | Joseph O. Moore | L. Damon | E. Attar | L. Maness | M. O'donnell | P. Shami | Mike G Martin | E. Coutre
[1] Paola Fazi,et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.
[2] M. Baccarani,et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. , 2011, Blood.
[3] E. Estey,et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] T. Naoe,et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. , 2006, Blood.
[5] E. Estey,et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. , 2006, Blood.
[6] Yuan-fang Liu,et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[7] C. Bloomfield,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .
[8] J. Miguel,et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.
[9] Wei Tang,et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.